Compare MYO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | XLO |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 56.9M |
| IPO Year | 2017 | 2021 |
| Metric | MYO | XLO |
|---|---|---|
| Price | $1.28 | $9.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 631.6K | 9.5K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | $43,766,000.00 |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.59 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | 589.88 |
| 52 Week Low | $0.61 | $0.46 |
| 52 Week High | $1.89 | $9.90 |
| Indicator | MYO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 48.51 |
| Support Level | $0.92 | $8.52 |
| Resistance Level | $1.89 | $9.15 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 5.05 | 57.33 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.